drugset
drugset / Trial / NCT06783114

A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults

NCT06783114 ↗

Phase 2/3 Recruiting 254 enrolled Chongqing Claruvis Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, multi-center phase II/III study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults

Timeline

Start
2024-09-14
Primary completion
2026-09-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 200 iu Intramuscular
Subject YY001 Protein / enzyme biologic 200 iu Intramuscular
Subject YY001 Protein / enzyme biologic 400 iu Intramuscular

Indications

No indication recorded.